Ocata Therapeutics Announces New Pre-Clinical Data to be Reported at the International Congress on Systemic Lupus Erythematosus
July 14 2015 - 8:30AM
Business Wire
Promising Potential Therapeutic Activity from
the Company’s Proprietary HMC™ Platform to be presented in Vienna,
Austria on September 4, 2015
Ocata Therapeutics, Inc. (“Ocata” or “the Company”;
NASDAQ:OCAT), a leader in the field of Regenerative
OphthalmologyTM, announced today that data will be presented at
the 11th International Congress on Systemic Lupus
Erythematosus, taking place in Vienna, Austria from September
2-6.
The results demonstrate promising potential
therapeutic activity of a pluripotent stem cell-derived
product for the treatment of autoimmune diseases such as lupus
nephritis and Crohn's disease using Ocata’s proprietary
Hemangio-derived Mesenchymal Cell (HMCTM) platform. This unique and
proprietary HMC product has been shown to have highly
potent immune-modulatory and anti-inflammatory activity
and is potentially well-suited for commercial scale up
with retention of therapeutic potency.
The data describes both ex-vivo and in-vivo evidence in a
highly regarded pre-clinical model of lupus nephritis.
Top line data supports a prior proof-of-concept study which showed
that HMC treatment increased the lifespan of the lupus-prone mice.
The current study expands upon the initial results and examines how
HMCs significantly inhibit the progression of otherwise fatal
glomerulonephritis. The abstract will be presented at the Vienna
Congress Center on Friday, September 4, 2015.
“This presentation at the
leading lupus meeting is an important first step
in developing potential new breakthrough treatments
for disabling autoimmune diseases like lupus
nephritis, where there is no cure available today,” said Paul
K. Wotton, Ph.D., President and Chief Executive
Officer. “Our preclinical research and patent estate
firmly anchors our leading position in the development of this
novel Restorative
Immunology™ platform and gives Ocata the
ability to partner the non-ophthalmic uses of its
technology for the treatment of devastating autoimmune
diseases.”
About Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. is a clinical stage biotechnology
company focused on the development and commercialization of
regenerative ophthalmology therapeutics. Ocata’s most advanced
products are in clinical trials for the treatment of Stargardt’s
macular degeneration, dry age-related macular degeneration, and
myopic macular degeneration. Ocata’s intellectual property
portfolio includes pluripotent stem cell platforms – hESC and
induced pluripotent stem cell (iPSC) – and other cell therapy
research programs. For more information, visit www.ocata.com.
Forward-Looking Statements
All statements, other than historical facts, contained in this
news release, including statements regarding Ocata’s belief
regarding the potential therapeutic activity of a pluripotent stem
cell-derived product in the treatment of auto immune diseases using
Ocata’s proprietary HMC platform, Ocata’s belief that its HMC
product is well-suited for commercial scale up and its
retention of therapeutic potency, the effect of Ocata’s
pre-clinical research and patent estate on the development of its
product platforms, and any other statements about Ocata’s future
expectations, beliefs, goals, plans, results or prospects expressed
by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Any statements that are not statements of historical fact
(including statements containing the words “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates,” and similar
expressions) should also be considered to be forward-looking
statements. There are a number of important factors that could
cause actual results or events to differ materially from those
indicated by such forward-looking statements, including: the fact
that Ocata has no product revenue and no products approved for
marketing; Ocata’s limited operating history; Ocata’s need for and
limited sources of future capital; potential failures or delays in
obtaining regulatory approval of products; risks inherent in the
development and commercialization of potential products; reliance
on new and unproven technology in the development of products; the
need to protect Ocata’s intellectual property; the challenges
associated with conducting and enrolling clinical trials; the risk
that the results of clinical trials may not support Ocata’s product
candidate claims; the risk that physicians and patients may not
accept or use Ocata’s products, even if approved; Ocata’s reliance
on third parties to conduct its clinical trials and to formulate
and manufacture its product candidates; and economic conditions
generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Ocata’s periodic reports, including the Annual
Report on Form 10-K for the fiscal year ended December 31, 2014.
Forward-looking statements are based on the beliefs, opinions, and
expectations of Ocata’s management at the time they are made, and
Ocata does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based
on the beliefs, opinions, and expectations of Ocata’s management at
the time they are made, and Ocata does not assume any obligation to
update its forward-looking statements if those beliefs, opinions,
expectations, or other circumstances should change. There can be no
assurance that Ocata’s future clinical trials will be successful or
that the results of previous clinical studies will lead to
commercialization or products or therapies.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150714005548/en/
Ocata Therapeutics, Inc.Investors:Westwicke PartnersJohn
Woolford, 443-213-0506john.woolford@westwicke.comorPress:Russo
PartnersDavid Schull,
858-717-2310david.schull@russopartnersllc.com
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Apr 2023 to Apr 2024